Sight Sciences, Inc.

The company develops interventional technologies for eyecare providers to treat eye diseases. Its mission is to preserve, protect, and restore natural physiological functionality to diseased eyes through products with proven clinical evidence that offer superior effectiveness and minimize complications. The company aims to create an interventional mindset in eyecare, with technologies used in procedures that replace conventional approaches. Initial product development has focused on glaucoma and dry eye disease (DED). The estimated annual addressable U.S. market for products in its Interventional Glaucoma segment is approximately $6.0 billion. This includes approximately $1.0 billion in the Combination Cataract Market, which involves procedures for primary open-angle glaucoma (POAG) patients combined with a cataract procedure. The remaining $5.0 billion is in the Standalone Market, for procedures performed on POAG patients without simultaneous cataract surgery. The U.S. market for dry eye treatments was $2.4 billion in 2025.